Turkish Validity And Reliability Of The Hammersmith Infant Neurological Evaluation (Hine)
Launched by SANKO UNIVERSITY · Feb 4, 2020
Trial Information
Current as of June 22, 2025
Completed
Keywords
ClinConnect Summary
The diagnosis of CP, which can be observed with high risk infants, is based on the observation of many neurological and clinical signs. The diagnosis usually takes place between 12-24 months. In the past years, before 12-24 months, it was seen as a hidden or silent period that could not be fully defined in terms of CP. However, today this definition has been found invalid because the diagnosis of 'high risk of CP' or CP can be predicted precisely before the corrected 6 months.There are 3 methods with the best predictable validity of determining CP before the corrected 5-month period: Neonat...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Infants with periventricular hemorage, intracranial hemorage,grade 2, 3, 4, cystic periventricular leukomalacia, stage 3 hypoxic ischemic encephalopathy, neonatal bilirubin encephalopathy (kernicterius), perinatal stroke, perinatal asphyxia, hydrocephalus
- • Chronic lung disease, respiratory lung disease (RDS), broncho pulmonary dysplasia and babies with long-term o₂ support
- • Gram negative bacterial sepsis, necrotizing enterocolitis (NEC), infantile apnea, preterm babies with cerebral malformation
- • Low Apgar score (3 and below), Preterm babies with intrauterine growth retardation, multiple births (twins, triplets), Premature Retinopathy (ROP)
- • Infants with prolonged severe hypoglycaemia and hypocalcemia
- • Surgical conditions such as diaphragmatic hernia or tracheoesophageal fistula
- • Infants who are small for gestational age (small for gestational age, sga, less than 3rd percentile) or large for gestational age (large for gestational age, LGA, greater than 97th percentile)
- • Infants who received mechanical ventilation for more than 24 hours
- • Infants younger than 32 gestational weeks and under 1500 kilograms
- Exclusion Criteria:
- • Infants with congenitalmal formation (spina bifida, congenital muscular torticollis, arthrogryposis multiplex congenita..vs)
- • Infants diagnosed with metabolic and genetic diseases (down syndrome, spinal muscular atrophy, duchenne muscular dystrophy..vs)
- • Postterm Infants still dependent on intubation and mechanical ventilator at 3 months.
About Sanko University
Sanko University is a distinguished academic institution dedicated to advancing medical research and education. With a strong emphasis on clinical trials, the university fosters innovative studies aimed at improving patient outcomes and contributing to the broader healthcare landscape. Leveraging its state-of-the-art facilities and a team of experienced researchers, Sanko University collaborates with various stakeholders to explore cutting-edge therapies and treatments. The institution is committed to ethical research practices and the highest standards of scientific rigor, ensuring that all clinical trials align with regulatory guidelines and prioritize participant safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gaziantep, şehitkamil, Turkey
Patients applied
Trial Officials
hatice adıgüzel, PhD cd.
Principal Investigator
sanko Üniversitesi
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials